ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Down – Here’s Why

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) gapped down before the market opened on Friday . The stock had previously closed at $82.63, but opened at $77.09. ANI Pharmaceuticals shares last traded at $76.13, with a volume of 142,181 shares.

ANI Pharmaceuticals News Roundup

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted EPS was $2.21, above the roughly $2.01-$2.04 analyst estimates and up from $1.80 a year earlier. Revenue reached $266.0 million, exceeding estimates near $260 million and increasing 25.9% year over year. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Cortrophin Gel revenue rose 43.5% to $117.1 million, while adjusted EBITDA increased 32.4% to $71.6 million. Management also reported encouraging early demand from its expansion into gout treatment, with the expanded sales organization fully operational by the end of June. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed 2026 total revenue guidance of $1.08 billion-$1.14 billion and adjusted EBITDA guidance of $285 million-$300 million. Adjusted EPS guidance of $9.19-$9.69 is also above the current consensus estimate of $9.10, and the company has authorization to repurchase up to $100 million of stock. Compared to Estimates, ANI Q2 Earnings: A Look at Key Metrics
• Neutral Sentiment: Generics revenue grew 9.7% to $99.1 million, supported by new launches, and the company has introduced 12 generic products year to date. ANI ended the quarter with $360.2 million in cash and generated $115 million in operating cash flow during the first half.
• Negative Sentiment: Management reduced 2026 Cortrophin Gel revenue guidance to $520 million-$540 million from $540 million-$575 million. Although the new range still implies 50%-55% annual growth, the cut likely disappointed investors counting on faster commercialization of the gout opportunity.
• Negative Sentiment: GAAP gross margin declined to 62.4% from 64.7%, partly because of a higher mix of royalty-bearing products and the non-recurrence of prior-year revenue. ILUVIEN revenue fell 16.1% to $18.7 million, while Brands revenue declined 10.5%.

Analyst Ratings Changes

Several research firms recently weighed in on ANIP. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim reiterated a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Finally, Canaccord Genuity Group assumed coverage on shares of ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 target price for the company. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $105.00.

ANI Pharmaceuticals Stock Performance

The stock has a market capitalization of $1.79 billion, a P/E ratio of 19.70 and a beta of 0.44. The company has a 50 day simple moving average of $81.03 and a 200-day simple moving average of $79.38. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the completion of the transaction, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. This trade represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the sale, the director directly owned 38,432 shares in the company, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 88,029 shares of company stock valued at $6,954,472. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANIP. KBC Group NV purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth $28,000. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the first quarter valued at $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares during the period. Kemnay Advisory Services Inc. bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $48,000. Finally, State of Wyoming purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $50,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.